According to the performance report for the third quarter of 2023 released by Yuyue Medical, a leading domestic medical device company, in the first three quarters, the company achieved operating income of 666.3 billion yuan, an increase of 30 over the same period last year23%；Net profit attributable to shareholders of listed companies219.1 billion yuan, an increase of 92 over the same period last year93%；Net cash flow from operating activities174.6 billion yuan, a year-on-year increase of 4978%。The growth rate of net profit attributable to the parent company and net cash flow is higher than that of revenue, which means that Yuyue Medical is continuing to release profit potential.
Being able to do this is closely related to Yuyue Medical's continuous R&D investment and forward-looking strategic layout. On the basis of continuously increasing R&D investment, Yuyue Medical has achieved a series of important R&D achievements.
In September this year, Yuyue Medical launched the third-generation Breathcare III sleep apnea machine, which condenses 216 intellectual property rights accumulated by Yuyue in the field of ventilators in the past 10 years, adopts self-developed low-noise and high-efficiency fans and a new integrated airway design, and fills the gap in the high-end market of domestic sleep apnea machines with three highlights: comfort, quietness and intelligence. According to statistics, there are 1With the 7.6 billion patients with sleep apnea syndrome and nearly 100 million patients with chronic obstructive pulmonary disease, with the continuous improvement of people's awareness of chronic diseases of the respiratory system, the breathing track is long and snowy, and the market space of home non-invasive ventilators is expected to gradually increase.
Previously, Yuyue Medical also launched a new generation of CGM (continuous glucose monitoring system) product, Anagnex AnytimeCT3 CT15, to meet the needs of blood glucose management in multiple scenarios and provide patients with diabetes care solutions with better clinical effect, comfort, portability and safety. In the first aid sector, Yuyue Pumekang AED has opened the road of fully independent domestic AED production and sales, and is in the forefront of the world in key indicators such as defibrillation energy, boot speed, algorithm analysis, and battery life.
With the continuous improvement of the R&D system and R&D team building, Yuyue has a young team that dares to innovate and practice, and has established 12 R&D centers in Shanghai, Nanjing, Suzhou, Danyang, Germany, Italy and other places. Cooperative research and development and other ways to continuously improve innovation capabilities, maintain the company's sustainable development momentum.